BCAB

BioAtla (BCAB)

About BioAtla (BCAB)

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Details

Daily high

$0.53

Daily low

$0.49

Price at open

$0.50

52 Week High

$4.02

52 Week Low

$0.45

Market cap

28.9M

Dividend yield

0.00%

Volume

619,180

Avg. volume

1.3M

P/E ratio

-.29

BioAtla News